Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CryoPort, Inc. stock logo
CYRX
CryoPort
$15.26
+0.7%
$15.33
$6.69
$16.89
$769.10M1.88591,546 shs223,486 shs
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
$76.63
+0.2%
$27.30
$9.10
$76.65
$1.06B2.85504,264 shs2.01 million shs
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
$11.58
+0.1%
$12.62
$11.35
$16.77
$198.09M0.93429,649 shs66,468 shs
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$7.83
-0.8%
$8.27
$3.79
$11.45
$770.37M2.361.46 million shs758,304 shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CryoPort, Inc. stock logo
CYRX
CryoPort
-1.43%-3.56%-5.30%+50.01%+92.99%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
+39.65%+61.09%+263.77%+189.88%+559.48%
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
+0.70%-1.62%-12.28%-7.81%-68.10%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
+0.77%-6.63%-15.07%+5.91%+12.71%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CryoPort, Inc. stock logo
CYRX
CryoPort
$15.26
+0.7%
$15.33
$6.69
$16.89
$769.10M1.88591,546 shs223,486 shs
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
$76.63
+0.2%
$27.30
$9.10
$76.65
$1.06B2.85504,264 shs2.01 million shs
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
$11.58
+0.1%
$12.62
$11.35
$16.77
$198.09M0.93429,649 shs66,468 shs
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$7.83
-0.8%
$8.27
$3.79
$11.45
$770.37M2.361.46 million shs758,304 shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CryoPort, Inc. stock logo
CYRX
CryoPort
-1.43%-3.56%-5.30%+50.01%+92.99%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
+39.65%+61.09%+263.77%+189.88%+559.48%
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
+0.70%-1.62%-12.28%-7.81%-68.10%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
+0.77%-6.63%-15.07%+5.91%+12.71%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CryoPort, Inc. stock logo
CYRX
CryoPort
2.78
Moderate Buy$16.387.31% Upside
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
2.33
Hold$72.50-5.38% Downside
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
2.28
Hold$67.60483.77% Upside
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
2.91
Moderate Buy$17.11118.67% Upside

Current Analyst Ratings Breakdown

Latest RNA, CYRX, SLDB, and FBRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/28/2026
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
DowngradeOverweightEqual Weight$74.00 ➝ $77.00
7/27/2026
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Set Price Target$77.00
7/27/2026
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
DowngradeStrong-BuyHold
7/24/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Boost Price TargetBuy$17.00 ➝ $25.00
7/21/2026
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Initiated CoverageOverweight$74.00
7/21/2026
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Initiated CoverageOverweight$74.00
7/17/2026
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Reiterated RatingSell (D-)
7/8/2026
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Reiterated RatingSell (D-)
6/19/2026
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
UpgradeHold
6/18/2026
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Initiated CoverageOverweight$25.00
6/8/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Set Price Target$13.50
(Data available from 7/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CryoPort, Inc. stock logo
CYRX
CryoPort
$176.18M4.37N/AN/A$9.19 per share1.66
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/A$4.71 per shareN/A
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
$36.68M5.40N/AN/A$10.88 per share1.06
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/AN/AN/AN/A$2.28 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CryoPort, Inc. stock logo
CYRX
CryoPort
$78.30M$1.3511.30N/AN/A41.57%-7.92%-4.79%8/6/2026 (Estimated)
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$69.38M-$4.64N/AN/AN/AN/A-106.17%-85.50%8/13/2026 (Estimated)
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
-$322.30M-$0.97N/AN/AN/A-3,650.39%-44.92%-39.57%8/13/2026 (Estimated)
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$174.32M-$1.95N/AN/AN/AN/A-73.42%-61.13%8/11/2026 (Estimated)

Latest RNA, CYRX, SLDB, and FBRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$0.9248N/AN/AN/AN/AN/A
8/13/2026Q2 2026
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
-$1.1833N/AN/AN/A$0.67 millionN/A
8/11/2026Q2 2026
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$0.43N/AN/AN/AN/AN/A
8/6/2026Q2 2026
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.20N/AN/AN/A$48.21 millionN/A
5/14/2026Q1 2026
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
-$1.05-$0.97+$0.08-$0.97$2.00 million$19.64 million
5/12/2026Q1 2026
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$0.40-$0.52-$0.12-$0.52N/AN/A
5/11/2026Q1 2026
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$1.16-$1.24-$0.08-$1.24N/AN/A
5/4/2026Q1 2026
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.20-$0.23-$0.03-$0.25$44.86 million$47.80 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/AN/A
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/AN/AN/AN/AN/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CryoPort, Inc. stock logo
CYRX
CryoPort
N/A
2.09
2.00
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/A
2.75
2.75
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/A
9.20
11.57
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/A
13.10
13.10

Institutional Ownership

CompanyInstitutional Ownership
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
77.63%
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
81.46%

Insider Ownership

CompanyInsider Ownership
CryoPort, Inc. stock logo
CYRX
CryoPort
9.50%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
4.40%
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
3.83%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
2.66%
CompanyEmployeesShares OutstandingFree FloatOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.40 million45.61 millionOptionable
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
513.89 million13.28 millionOptionable
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
19017.11 million149.21 millionOptionable
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
10098.45 million95.83 millionOptionable

Recent News About These Companies

Solid Biosciences Adjusts Board Classes in Governance Move
J.P. Morgan Issues a Buy Rating on Solid Biosciences (SLDB)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
CryoPort stock logo

CryoPort NASDAQ:CYRX

$15.26 +0.11 (+0.73%)
As of 03:20 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Forte Biosciences stock logo

Forte Biosciences NASDAQ:FBRX

$76.62 +0.13 (+0.16%)
As of 03:20 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Avidity Biosciences stock logo

Avidity Biosciences NASDAQ:RNA

$11.58 +0.01 (+0.09%)
As of 03:03 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Solid Biosciences stock logo

Solid Biosciences NASDAQ:SLDB

$7.82 -0.07 (-0.82%)
As of 03:20 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.